Sei Investments Co. Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Sei Investments Co. trimmed its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 98,309 shares of the biopharmaceutical company's stock after selling 17,828 shares during the period. Sei Investments Co. owned 0.11% of Ultragenyx Pharmaceutical worth $4,136,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares in the last quarter. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $42,000. Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $93,000. Finally, Van ECK Associates Corp lifted its stake in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 273 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded down $0.29 during mid-day trading on Monday, hitting $32.14. The stock had a trading volume of 1,170,671 shares, compared to its average volume of 795,159. The business has a 50 day moving average price of $40.61 and a two-hundred day moving average price of $45.75. Ultragenyx Pharmaceutical Inc. has a 1 year low of $30.45 and a 1 year high of $60.37. The firm has a market cap of $3.02 billion, a P/E ratio of -5.07 and a beta of 0.61.

Remove Ads

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Piper Sandler decreased their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. HC Wainwright restated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. upped their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Finally, Wedbush restated a "neutral" rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Howard Horn sold 1,785 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares of the company's stock, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 in the last 90 days. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.